Evaluation of Tumor Size Response Metrics to Predict Survival in Oncology Clinical Trials
- 13 January 2014
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 95 (4) , 386-393
Abstract
Model-based drug development in oncology is still lagging despite a good momentum in the clinical pharmacology and pharmacometry community in the past few years. The failure rate of late-stage oncology studies is one of the highest across therapeutic areas. The modeling of the relationship between longitudinal tumor size and overall survival has been proposed to enhance learning in early clinical studies, to predict overall survival, and to simulate clinical trials. This approach has the potential to support proof of concept, early clinical decisions, and design of late-stage trials, but it is not yet widely integrated into the oncology drug development process. In this article, we review the state of these modeling efforts and discuss several key applications of these models. We conclude by suggesting a few paths forward.Keywords
This publication has 47 references indexed in Scilit:
- Clinical Approval Success Rates for Investigational Cancer DrugsClinical Pharmacology & Therapeutics, 2013
- The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of MeasurementClinical Cancer Research, 2013
- Industry and Regulatory Performance in 2012: A Year in ReviewClinical Pharmacology & Therapeutics, 2013
- Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug DevelopmentClinical Pharmacology & Therapeutics, 2013
- Models of Excellence: Improving Oncology Drug DevelopmentClinical Pharmacology & Therapeutics, 2012
- How to improve R&D productivity: the pharmaceutical industry's grand challengeNature Reviews Drug Discovery, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal CancerJournal of Clinical Oncology, 2007
- Measuring response in a post-RECIST world: from black and white to shades of greyNature Reviews Cancer, 2006